Dr Brahmer on First-line Tremelimumab/Durvalumab Plus Chemotherapy in NSCLC
March 23rd 2023Julie Renee Brahmer, MD, discusses the use of tremelimumab plus durvalumab and platinum-based chemotherapy for the first-line treatment of patients with non–small cell lung cancer, and how decisions can be made between this regimen and nivolumab plus ipilimumab and chemotherapy.
Read More
Dr. Brahmer on Immunotherapy Beyond PD-1/L1 in NSCLC
February 13th 2019Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the potential for immunotherapy beyond PD-1 and PD-L1 checkpoints in non–small cell lung cancer.
Read More
Dr. Brahmer on Managing Immune-Related AEs in Lung Cancer
January 26th 2019Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing immune-related adverse events in lung cancer.
Read More
Dr. Brahmer on Biomarkers for Immune Response in NSCLC
December 18th 2018Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses biomarkers for immune response in non–small cell lung cancer.
Read More